Vancomycin Taper to Prevent Recurrent Clostridioides Difficile

Indirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10-days of fidaxomicin for the prevention of recurrent Clostridioides difficile infections (rCDI). The aim of this trial is: 1\) For first episodes and first recurrences of CDI, to test whether a vancomycin P-T is non-inferior to 10-days of fidaxomicin for the prevention of rCDI at 56 days

NCT Number	NCT07328971
Lead Sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions	Clostridia Difficile Colitis
Enrollment	500 participants
Start Date	2026-04-24
Primary Completion	2030-06-01 (estimated)
Study Completion	2030-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-24